(July 10, 2018, 10:52 AM EDT) -- ALEXANDRIA, Va. — A patented method of treating human onychomycosis caused by Trichophyton rubrum or Trichophyton mentagrophytes with topical administration of a composition containing tavaborole would have been obvious to a person of skill in the art (POSITA), Mylan Pharmaceuticals Inc. asserts in a July 6 petition for inter partes review by the Patent Trial and Appeal Board (Mylan Pharmaceuticals Inc. v. Anacor Pharmaceuticals Inc., No. IPR2018-01358, PTAB)....